Synergy Pharma Considers Possible Sale

Mar 26, 2015

Bloomberg

New York-based Synergy Pharmaceuticals, developer of gastrointestinal disorder drugs, is talking to advisers about a potential sale of the company, according to Bloomberg sources.

Earlier this month, Salix -- which competes with Synergy in the gastrointestinal field -- was purchased by Valeant Pharmaceuticals for $10 billion.

Bloomberg sources say the sale of Synergy may depend on the results of a late-stage trial of IBS drug plecanatide, which should be announced in May.

Read the Bloomberg article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments